home / stock / cmvlf / cmvlf news

CMVLF News and Press, Cellectis Romainville Ord

Stock Information
Company Name: Cellectis Romainville Ord
Stock Symbol: CMVLF
Market: OTC
Website: cellectis.com
Menu
CMVLF CMVLF Quote CMVLF Short CMVLF News CMVLF Articles CMVLF Message Board
Get CMVLF Alerts

News, Short Squeeze, Breakout and More Instantly...
CMVLF - Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
CMVLF - Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...

CMVLF - Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publicatio...

CMVLF - Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Co...
CMVLF - Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

2024-05-30 14:06:04 ET Cellectis S.A. (CLLS) Q1 2024 Earnings Conference Call May 29, 2024, 08:00 AM ET Company Participants Arthur Stril - Interim-CFO André Choulika - CEO Mark Frattini - Chief Medical Officer Conference Call Participants Gena W...

CMVLF - Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...

CMVLF - Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual...
CMVLF - Cellectis Reports Financial Results for First Quarter 2024

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 •  Conference call and webcast sched...

CMVLF - Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financia...

CMVLF - Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biote...
Next 10